<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04706741</url>
  </required_header>
  <id_info>
    <org_study_id>ABY-035-203</org_study_id>
    <nct_id>NCT04706741</nct_id>
  </id_info>
  <brief_title>A Trial of the Efficacy and Safety Trial of ABY-035 in the Treatment and Prevention of Relapse/Recurrence of Non-anterior Uveitis</brief_title>
  <acronym>LINNAEA</acronym>
  <official_title>A Phase 2 Trial of the Efficacy and Safety of the Interleukin-17A Inhibitor ABY-035 in the Treatment and Prevention of Relapse/Recurrence of Non-infectious Intermediate, Posterior or Pan-uveitis, Including an Initial Pilot Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affibody</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affibody</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multinational, multicenter, phase 2 proof-of-concept trial to explore the efficacy&#xD;
      and safety of ABY-035 in treating and preventing relapse/recurrence of disease activity in&#xD;
      patients with non-Infectious Intermediate, Posterior, Pan-Uveitis with significant BL disease&#xD;
      activity despite treatment with stable doses of corticosteroids (≥7 to ≤40 mg/day oral&#xD;
      prednisolon or equivalent).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The primary purpose of the study is prevention of relapse/recurrence of Noninfectious Intermediate, Posterior or Pan-uveitis&#xD;
The trial consist of two parts, a pilot part - Part A - and Part B&#xD;
Part A includes one treatment arm (Arm-0)&#xD;
Part B is planned to include 3 treatment arms - to which the subjects will be randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Part A will be open-label. Part B (arm-2 and arm-3) will be masked with regards to ABY-035/Placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>Week 10 to Week 50</time_frame>
    <description>Treatment Failure&quot; is defined as Yes/No by visit by meeting at least 1 of the following criteria in at least one eye:&#xD;
Inflammatory, chorioretinal and/or inflammatory retinal vascular lesions - New active, or worsening of previously identified inflammatory lesions relative to BL&#xD;
ACC Count - Inability to achieve ≤ 0.5+ (Week 10) or 2-step increase relative to best state achieved (&lt;Week 10)&#xD;
Vitreous Haze - Inability to achieve ≤ 0.5+ (Week 10) or 2-step increase relative to best state achieved (&lt;Week 10)&#xD;
Visualt acuity - Worsening of BCVA by ≥ 15 letters relative to best state achieved (not due to cataract)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>ABY-035 and maintenance corticosteroid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABY-035 + Prednisolon/Prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABY-035 and corticosteroid burst</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABY-035 + Prednisolon/Prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and corticosteroid burst</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + Prednisolon/Prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABY-035</intervention_name>
    <description>ABY-035 is an Interleukin-17 Inhibitor that will be administered subcutaneously</description>
    <arm_group_label>ABY-035 and corticosteroid burst</arm_group_label>
    <arm_group_label>ABY-035 and maintenance corticosteroid dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone/Prednisone</intervention_name>
    <description>Background Corticosteroid</description>
    <arm_group_label>ABY-035 and corticosteroid burst</arm_group_label>
    <arm_group_label>ABY-035 and maintenance corticosteroid dose</arm_group_label>
    <arm_group_label>Placebo and corticosteroid burst</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to ABY-035</description>
    <arm_group_label>Placebo and corticosteroid burst</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥18 years of age at SCR&#xD;
&#xD;
          2. Previously documented medical history with diagnosed unilateral or bilateral NIIPPU&#xD;
&#xD;
          3. Active disease at BL defined by the presence of at least 1 of the following criteria&#xD;
             in at least one eye despite treatment with stable doses of corticosteroids for at&#xD;
             least 2 weeks:&#xD;
&#xD;
               1. Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion&#xD;
                  by Dilated Indirect Ophthalmoscopy (DIO) and Fundus Photography to determine&#xD;
                  whether a lesion is active or inactive (the central reader's assessment using&#xD;
                  Fundus Photography is required to confirm eligibility).&#xD;
&#xD;
               2. ≥2+ vitreous haze ( NEI/SUN criteria) by DIO and Fundus Photography (the central&#xD;
                  reader's assessment using Fundus Photography is required to confirm eligibility).&#xD;
&#xD;
          4. On treatment with oral corticosteroids (≥7 to ≤40 mg/day oral prednisolon or&#xD;
             equivalent) at a stable dose for at least 2 weeks before BL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject with isolated anterior uveitis&#xD;
&#xD;
          2. Subject with Occlusive Behçet's disease, Acute Posterior Multifocal Placoid Pigment&#xD;
             Epitheliopathy, Acute Posterior Pigment Epithelitis, Multiple Evanescent White Dot&#xD;
             Syndrome, Punctate Inner Choroiditis or serpiginous choroidopathy&#xD;
&#xD;
          3. Subject with confirmed or suspected infectious uveitis, including but not limited to&#xD;
             infectious uveitis due to TB, syphilis, cytomegalovirus, Lyme disease, toxoplasmosis,&#xD;
             Human T-Lymphotropic Virus Type 1 infection, Whipple's disease, herpes zoster virus,&#xD;
             and herpes simplex virus&#xD;
&#xD;
          4. Subject with corneal or lens opacity that precludes visualization of the fundus or&#xD;
             that likely requires cataract surgery during the duration of the trial&#xD;
&#xD;
          5. Planned (elective) eye surgery within 80 weeks after BL&#xD;
&#xD;
          6. History of prior refractive laser surgery, retinal laser photocoagulation, or&#xD;
             neodymium-doped yttrium aluminium garnet posterior capsulotomy within 30 days before&#xD;
             BL&#xD;
&#xD;
          7. History of any other prior ocular surgery within 90 days before BL&#xD;
&#xD;
          8. Subject with intraocular pressure (IOP) of ≥25 mmHg while on ≥2 glaucoma medications&#xD;
             or evidence of glaucomatous optic nerve injury&#xD;
&#xD;
          9. Subject with severe vitreous haze that precludes visualization of the fundus at BL&#xD;
&#xD;
         10. Subject has a contraindication for mydriatic eye drops OR subject cannot be dilatated&#xD;
             sufficiently well to permit good fundus visualization&#xD;
&#xD;
         11. Subject with BCVA &lt;20 letters (ETDRS) in at least one eye at BL&#xD;
&#xD;
         12. Subject with intermediate uveitis or panuveitis who has presence or history of whitish&#xD;
             exudates on the inferior pars plana (snowbanking) or vitreal inflammatory aggregates&#xD;
             (snowballs) in combination with a medical history or signs or symptoms suggestive of a&#xD;
             demyelinating disease such as multiple sclerosis&#xD;
&#xD;
         13. Subject with proliferative or severe non-proliferative diabetic retinopathy or&#xD;
             clinically significant macular edema due to diabetic retinopathy&#xD;
&#xD;
         14. Subject with neovascular/wet age-related macular degeneration&#xD;
&#xD;
         15. Subject with an abnormality of the vitreo-retinal interface (i.e., vitreomacular&#xD;
             traction, epiretinal membranes, etc.) with the potential for macular structural damage&#xD;
             independent of the inflammatory process&#xD;
&#xD;
         16. Subject with a history of active scleritis within 12 months of SCR Criteria that&#xD;
             relate to comorbidity&#xD;
&#xD;
         17. Uncontrolled inflammatory bowel disease&#xD;
&#xD;
         18. Infection requiring treatment with IV anti-infectives within 30 days before BL or oral&#xD;
             anti-infectives within 14 days before BL&#xD;
&#xD;
         19. Subject with any active infection that based on the investigator's clinical assessment&#xD;
             makes the subject an unsuitable candidate for the trial&#xD;
&#xD;
         20. History or any signs of lymphoproliferative disease, or a known malignancy or a&#xD;
             history of malignancy within the previous 3 years (except for basal cell or squamous&#xD;
             cell carcinoma of the skin that had been fully excised with no evidence of recurrence)&#xD;
             Criteria that relate to laboratory testing&#xD;
&#xD;
         21. A positive test for subclinical/latent TB infection (i.e. positive QuantiFERON®-TB&#xD;
             Gold test or equivalent product) suggestive of TB at SCR will require that the subject&#xD;
             is thoroughly evaluated for active tuberculosis. If the subject is diagnosed with&#xD;
             latent TB and active TB can be ruled out, the subject can be included if the subject&#xD;
             has gone through an adequate course of prophylaxis as per local standard of care 12&#xD;
             weeks prior to SCR.&#xD;
&#xD;
         22. Positive Fluorescent treponemal (FTA)- absorption test (syphilis)&#xD;
&#xD;
         23. Subject with intolerance to high-dose oral corticosteroids (equivalent to oral&#xD;
             prednisolon 1 mg/kg/day or 60 mg/day)&#xD;
&#xD;
         24. The subject has received any biologic therapy (including ABY-035 or any other IL-17i&#xD;
             or IL-17 receptor inhibitor, e.g. secukinumab, ixekizumab, brodalumab or&#xD;
             anti-TNF-alpha therapy) within 8 weeks before BL.&#xD;
&#xD;
         25. Subject on &gt;1 concomitant non-biologic NCSIT&#xD;
&#xD;
         26. Subject on 1 concomitant non-biologic NCSIT:&#xD;
&#xD;
             a) But the medication is not listed as permissible b) The medication is listed as&#xD;
             permissible, but the dose has not been stable within the last 3 months before BL c)&#xD;
             The medication is listed as permissible, but the dose exceeds the allowable level; to&#xD;
             be acceptable, the dose needs to be: i) Methotrexate (MTX) ≤25 mg/week ii) CsA ≤4&#xD;
             mg/kg/day iii) Mycophenolate mofetil ≤2 grams/day or an equivalent drug to&#xD;
             mycophenolate mofetil (e.g., mycophenolic acid) at an equivalent dose approved by the&#xD;
             Medical monitor iv) Azathioprine ≤175 mg/day v) Tacrolimus (oral formulation) ≤8&#xD;
             mg/day&#xD;
&#xD;
        28] The subject has received Retisert®, Iluvien®, or Yutiq® (glucocorticosteroids implant)&#xD;
        within 3 years before BL or who has had complications related to the device. The subject&#xD;
        has had any of these glucocorticosteroids implant (glucocorticosteroid implant) removed&#xD;
        within 90 days before BL or has had complications related to the removal of the device 29]&#xD;
        The subject has received intraocular or periocular corticosteroids within 90 days before BL&#xD;
        30] The subject has received Ozurdex® (dexamethasone implant) within 6 months before BL 31]&#xD;
        The subject has received intravitreal methotrexate within 90 days before BL 32] The subject&#xD;
        has received intravitreal anti- Vascular Endothelial Growth Factor (VEGF) therapy:&#xD;
&#xD;
          1. within 45 days of BL for Lucentis® (ranibizumab) or Avastin® (bevacizumab)&#xD;
&#xD;
          2. or within 60 days of BL for anti-VEGF Trap (aflibercept)&#xD;
&#xD;
          3. or within 84 days of BL for Beovu® (brolucizumab) 33] Subject on systemic carbonic&#xD;
             anhydrase inhibitor within 1 week before SCR 34] Subject on cyclophosphamide within 30&#xD;
             days before BL 35] Prior or current use of chlorambucil&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karin Grünbaum</last_name>
    <phone>+46730718201</phone>
    <email>linnaea@affibody.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Per Dalen, MD, PhD</last_name>
    <email>linnaea@affibody.se</email>
  </overall_contact_backup>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

